Universal Beteiligungs und Servicegesellschaft mbH Raises Stock Position in Natera, Inc. (NASDAQ:NTRA)

Universal Beteiligungs und Servicegesellschaft mbH boosted its position in Natera, Inc. (NASDAQ:NTRA - Free Report) by 4.8% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 127,181 shares of the medical research company's stock after acquiring an additional 5,831 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned 0.09% of Natera worth $17,985,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD lifted its position in shares of Natera by 134.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company's stock worth $1,067,327,000 after purchasing an additional 3,871,862 shares during the period. JPMorgan Chase & Co. lifted its position in Natera by 43.7% during the 4th quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company's stock valued at $1,060,836,000 after acquiring an additional 2,036,396 shares during the period. Norges Bank purchased a new position in Natera during the 4th quarter valued at about $224,040,000. Vanguard Group Inc. raised its holdings in Natera by 7.7% in the fourth quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company's stock worth $1,949,697,000 after buying an additional 879,463 shares during the last quarter. Finally, Wellington Management Group LLP raised its holdings in Natera by 15.7% in the fourth quarter. Wellington Management Group LLP now owns 3,240,041 shares of the medical research company's stock worth $512,898,000 after buying an additional 439,778 shares during the last quarter. Institutional investors own 99.90% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on NTRA. Piper Sandler lifted their target price on shares of Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Thursday, May 15th. Wall Street Zen lowered shares of Natera from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th. UBS Group boosted their target price on shares of Natera from $211.00 to $218.00 and gave the company a "buy" rating in a research report on Friday, May 9th. Finally, Barclays boosted their target price on shares of Natera from $160.00 to $190.00 and gave the company an "overweight" rating in a research report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $184.63.

Natera Stock Performance

NTRA stock traded down $2.17 during mid-day trading on Friday, reaching $138.90. 1,202,980 shares of the stock traded hands, compared to its average volume of 1,211,392. Natera, Inc. has a one year low of $92.14 and a one year high of $183.00. The stock has a market capitalization of $18.97 billion, a PE ratio of -94.49 and a beta of 1.73. The business has a 50-day moving average price of $159.07 and a two-hundred day moving average price of $157.34.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, topping analysts' consensus estimates of ($0.59) by $0.09. The firm had revenue of $501.83 million for the quarter, compared to analysts' expectations of $446.68 million. Natera had a negative net margin of 10.36% and a negative return on equity of 18.29%. The business's revenue for the quarter was up 36.5% on a year-over-year basis. During the same period in the prior year, the business posted ($0.56) earnings per share. On average, equities analysts expect that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Natera news, CEO Steven Leonard Chapman sold 6,980 shares of the firm's stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $150.10, for a total transaction of $1,047,698.00. Following the completion of the transaction, the chief executive officer directly owned 185,182 shares of the company's stock, valued at approximately $27,795,818.20. This trade represents a 3.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Gail Boxer Marcus sold 4,299 shares of the firm's stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $167.36, for a total transaction of $719,480.64. Following the transaction, the director directly owned 8,118 shares of the company's stock, valued at $1,358,628.48. This represents a 34.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 58,271 shares of company stock valued at $9,075,247. 7.60% of the stock is owned by insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.